NATCO Pharma Launches Generic Pomalidomide in US Market

💊

, in partnership with Breckenridge, has launched Pomalidomide Capsules in the US market, a generic version of Pomalyst. The branded product recorded estimated sales of USD 3.2 billion for the 12 months ending September 2025, marking a significant opportunity in the oncology segment.